CRDF vs. PHVS, NRIX, PRAX, AKBA, SYRE, MLYS, SION, AVXL, ORIC, and LENZ
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Pharvaris (PHVS), Nurix Therapeutics (NRIX), Praxis Precision Medicines (PRAX), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Sionna Therapeutics (SION), Anavex Life Sciences (AVXL), Oric Pharmaceuticals (ORIC), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry.
Cardiff Oncology vs. Its Competitors
Pharvaris (NASDAQ:PHVS) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.
Cardiff Oncology has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Pharvaris has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,308.50%. Pharvaris' return on equity of -54.02% beat Cardiff Oncology's return on equity.
Pharvaris has a beta of -2.82, suggesting that its share price is 382% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Pharvaris currently has a consensus price target of $36.20, suggesting a potential upside of 101.11%. Cardiff Oncology has a consensus price target of $9.88, suggesting a potential upside of 170.55%. Given Cardiff Oncology's higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than Pharvaris.
In the previous week, Pharvaris and Pharvaris both had 2 articles in the media. Pharvaris' average media sentiment score of 1.22 beat Cardiff Oncology's score of 0.78 indicating that Pharvaris is being referred to more favorably in the media.
16.3% of Cardiff Oncology shares are held by institutional investors. 7.7% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Cardiff Oncology beats Pharvaris on 8 of the 14 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CRDF) was last updated on 7/8/2025 by MarketBeat.com Staff
Free CRDF Stock Alerts